Similar to 2020, there were increases in demand in 2021 for infusion pumps to treat COVID-19 patients. Initially, infusion pumps were requested for Covid patients connected to ventilators. Earlier last year, the FDA issued an emergency use authorization (EUA) for monoclonal antibody treatments bringing additional needs for infusion treatments in many alternate care settings. In addition to treatments from within hospitals and clinics, CMS approved infusions of monoclonal antibodies by home care providers for COVID patients.
Treatments like these in alternate care settings are key to understanding how the infusion industry will likely evolve in 2022.
Homecare Will Become a Common Infusion Setting…